Publicacións en colaboración con investigadores/as de Hospital de Cabueñes (10)

2024

  1. Prognostic Value of D-dimer to Lymphocyte Ratio (DLR) in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Validation Study in a National Cohort

    Viruses, Vol. 16, Núm. 3

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2015

  1. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes

    Diabetes Care, Vol. 38, Núm. 12, pp. 2211-2216

  2. Hypoglycemia in noncritically ill patients receiving total parenteral nutrition: A multicenter study. (Study group on the problem of hyperglycemia in parenteral nutrition; Nutrition area of the Spanish Society of Endocrinology and Nutrition)

    Nutrition, Vol. 31, Núm. 1, pp. 58-63

  3. Nutrition-related risk indexes and long-term mortality in noncritically ill inpatients who receive total parenteral nutrition (prospective multicenter study)

    Clinical Nutrition, Vol. 34, Núm. 5, pp. 962-967

  4. Prevalence of diabetes, prediabetes, and stress hyperglycemia: Insulin therapy and metabolic control in patients on total parenteral nutrition (prospective multicenter study)

    Endocrine Practice, Vol. 21, Núm. 1, pp. 59-67

2013

  1. Parenteral nutrition-associated hyperglycemia in non-critically iII inpatients increases the risk of in- hospital mortality (multicenter study)

    Diabetes Care, Vol. 36, Núm. 5, pp. 1061-1066

  2. The Subjective Global Assessment Predicts In-Hospital Mortality Better than Other Nutrition-Related Risk Indexes in Noncritically Ill Inpatients Who Receive Total Parenteral Nutrition in Spain (Prospective Multicenter Study)

    Journal of the Academy of Nutrition and Dietetics, Vol. 113, Núm. 9, pp. 1209-1218

2006

  1. Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial

    Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326

2003

  1. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage

    Clinical Endocrinology, Vol. 58, Núm. 4, pp. 471-481